Skip to content
Open access

Development of macrocyclic peptide inhibitors of Mycobacterium tuberculosis MurF via mRNA display with genetic reprogramming.

Aug 2026 · RSC Medicinal Chemistry · 0 citations
Medicine

Abstract

The development of new antibacterials for Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), remains critical due to the continued global burden of disease and the emergence of multi-drug resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains. The MurF enzyme, which catalyses the ATP-dependent ligation of d-Ala-d-Ala to a UDP-MurNAc-tripeptide precursor in peptidoglycan biosynthesis, represents a promising therapeutic target. In this work, random non-standard peptide integrated discovery (RaPID) mRNA display with genetic reprogramming of a non-canonical uracil-derived amino acid was applied to Mtb MurF, leading to the identification of several high-affinity thioether-linked cyclic peptide ligands, several of which also inhibited the catalytic activity of the Mtb MurX enzyme.

Read PDF

Similar papers

Aug 2026

Molecular insights into inhibitor action on the catalytic activity of Mycobacterium tuberculosis cystathionine β-synthase enzyme.

These findings provide a mechanistic rationale for MtbCBS inhibition, and the unexplored roles of these key residues can be considered in the design of next-generation inhibitors targeting CBS enzymes implicated in infectious diseases, cancer, and neurological disorders.

Sainath Polepalli, Anupam Roy, Bapan Mondal et al. · 0 citations
Review Open access Sep 2026

Structural features, activity relationships, and synthetic strategies of indole-based derivatives as antitubercular agents targeting mycolic acid biosynthesis

Tuberculosis (TB) is a severe airborne infectious disease caused by Mycobacterium tuberculosis ( M. tb ), primarily impacting the lungs and other organs. Antimicrobial resistance in TB is an emerging problem that requires immediate treatment and management. It is difficult to cure tuberculosis as there are increa...

Sandeep Bindra, Chetna Amrodiya, M. Abdelgawad et al. · 0 citations
Sep 2026

Synthesis of mannosides as potential inhibitors of PIMs biosynthesis in mycobacteria.

The discovery of new therapeutic targets for combating tuberculosis has become crucial due to the alarming increase in multi-drug resistant strains. The acyltransferase PatA, involved in the biosynthesis of phosphatidyl-myo-inositol mannosides (PIMs), key components of the mycobacterial cell wall, has recently been sho...

Julien Piechowiak, Julien Caillé, Estelle Gallienne · 0 citations
Sep 2026

TrmD: A Promising Antibacterial Target and Its Small-Molecule Inhibitors

Bacterial tRNA-(N1G37) methyltransferase (TrmD), a member of the SPOUT superfamily, plays a pivotal role in catalyzing the methyl group transfer from S-adenosyl-l-methionine to the N1 position of G37 in the pathway of post-transcriptional modifications of bacterial tRNA. In response to the urgent global clinical need...

Zhi-Wei Meng, Dian-Fu Xia, Xin-Tong Zhang et al. · 0 citations
Open access Sep 2026

The Flexible Peripheral Segments Modulate the Catalytic Activity of the FAD-Containing Monooxygenase EthA from Mycobacterium tuberculosis

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major global health concern, particularly due to the emergence of drug-resistant strains. FAD-containing monooxygenase EthA activates the antitubercular prodrug ethionamide (ETH) in Mtb. However, the structural and functional mechanisms of Mtb Eth...

Da-Feng Liu, Xie-Ping Sun, Feng Yu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.